Neurocrine Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Neurocrine Stock Quote
- Double Formation
* 155.00 USD | 1st Area Of Value | Subdivision 1
* A+ Set Up)) | Completed Survey
- Triple Formation
* 130.00 USD | 2nd Area Of Value | Subd
Neurocrine Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Neurocrine Stock Quote
- Double Formation
* Retracement | Not Numbered | A+ Set Up Area | Subdivision 1
* Wedge Structure | 117.00 USD & 106.00 USD | Subdivision 2
- Triple Formatio
Solid Growth but Misses Q2 Earnings TargetsNeurocrine Biosciences Inc. (NASDAQ: NBIX) is continuing to advance its position in the biotech sector, despite facing a slight setback in its Q2 2024 earnings report. The company posted revenue of $590.2 million, which was higher than analyst estimates of $545.9 million, representing a 30.4% year-o
(Potential Trade) NBIX(13 May 2024)
Disclaimer:
All information posted are the author's own trades/potential trades.
The author is not a certified Financial Advisor and do not have the certifications to provide financial advice.
These information are strictly for educational purposes only and do not constitute any finan
NBIX Biotechnology / Pharmaceutical Pre-earnings LONGNeurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th.
Investor and trader interest seems to be moderately increasing in the past week. The combined
MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket
before 7:45 AM
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges
Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidat
Neurocrine Biosciences (NBIX: NASDAQ)Neurocrine Biosciences (NBIX), a biotech company specializing in treatments for neurological, endocrine, and psychiatric disorders, is poised for opportunities in congenital adrenal hyperplasia (CAH). Analysts project NBIX to potentially achieve worldwide revenue of $660 million by fiscal year 2030,
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NBIX is featured.